People who suffer traumatic brain injuries or develop certain neurological conditions may need consistent treatments, including medications and other therapies. Sometimes, secondary conditions develop because of these traumas which impact behavior and other mental functions. These secondary conditions often exacerbate the original trauma.
Drugmakers are constantly creating new medications indicated to treat these conditions, but these manufacturers do not always seem to have patients’ best interests at heart. Sometimes, profit appears to trump patient well-being.
This “profit over patient” mentality seems to be playing out in a scandal involving the prescription drug Nuedexta and its manufacturer, Avanir Pharmaceuticals. A CNN investigation into the pharmaceutical company found Avanir may have been pushing healthcare professionals to dole out prescriptions of Nuedexta to patients who wouldn’t necessarily benefit from the drug. In some cases, the drug proved to be harmful. Meanwhile, Avanir raked in millions of dollars in sales from its first-in-class drug.